for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AtriCure Inc.

ATRC.OQ

Latest Trade

27.31USD

Change

0.67(+2.50%)

Volume

71,224

Today's Range

26.70

 - 

27.34

52 Week Range

22.57

 - 

34.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.65
Open
26.78
Volume
71,224
3M AVG Volume
5.62
Today's High
27.34
Today's Low
26.70
52 Week High
34.37
52 Week Low
22.57
Shares Out (MIL)
38.78
Market Cap (MIL)
1,033.36
Forward P/E
-30.08
Dividend (Yield %)
--

Next Event

Q3 2019 AtriCure Inc Earnings Release

Latest Developments

More

Atricure Enters Into Definitive Agreement To Acquire Sentreheart

AtriCure Reports Q2 Adjusted Loss Per Share $0.17

Atricure Reports Q1 Adj Loss Per Share Of $0.20

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AtriCure Inc.

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry

Medical Equipment & Supplies

Contact Info

7555 Innovation Way

+1.513.7554100

https://www.atricure.com

Executive Leadership

Scott William Drake

Independent Chairman of the Board

Michael H. Carrel

President, Chief Executive Officer, Director

Andrew Wade

Chief Financial Officer, Senior Vice President

Douglas J. Seith

Chief Operating Officer

Justin J. Noznesky

Senior Vice President, Marketing and Business Development

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

-1.050

2017

-0.960

2018

-0.620

2019(E)

-0.876
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.79
Price To Book (MRQ)
4.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
24.10
LT Debt To Equity (MRQ)
23.83
Return on Investment (TTM)
-7.88
Return on Equity (TTM)
-7.02

Latest News

Latest News

BRIEF-Atricure Inc Q1 Loss Per Share $0.31

* Q1 EARNINGS PER SHARE VIEW $-0.27 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Atricure Posts Q4 Loss Per Share $0.08

* ATRICURE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Atricure Inc Launches Atriclip Flex V Device In U.S.

* ATRICURE INC - LAUNCHES ATRICLIP FLEX•V DEVICE IN UNITED STATES Source text for Eikon: Further company coverage:

BRIEF-Atricure Sees FY 2018 Revenue About $190 Million To $196 Million

* FY2017 REVENUE VIEW $173.9 MILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Atricure reports Q3 loss per share $0.22

* Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

BRIEF-Atricure Q2 loss per share $0.21

* Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S

BRIEF-Atricure Inc reports Q1 loss per share $0.32

* Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S

BRIEF-Atricure names two new members to its board of directors

* Regina Groves and B. Kristine Johnson have been appointed to its board of directors

BRIEF-Atricure announces preliminary results

* Atricure announces preliminary results for fourth quarter and full year 2016

BRIEF-Hudson Executive Capital reports 5.6 pct stake in AtriCure

* Hudson Executive Capital reports 5.6 pct stake In AtriCure Inc as of Jan 17 - sec filing

BRIEF-AtriCure announces preliminary results for Q4 and FY 2016

* AtriCure announces preliminary results for fourth quarter and full year 2016

BRIEF-Atricure names Sven Wehrwein to its board of directors

* Atricure names Sven Wehrwein to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Atricure announces approval for Cryoice(TM) platform in Japan

* Atricure announces approval for the cryoice(tm) platform in Japan

BRIEF-Atricure Q3 loss per share $0.21

* Q3 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up